[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100301053":3},{"organization":4,"armGroups":7,"interventions":10,"overallOfficials":33,"centralContacts":38,"locations":47,"responsibleParty":64,"collaborators":10,"id":66,"slug":67,"hasResults":68,"nctId":69,"briefTitle":70,"officialTitle":71,"acronym":10,"eligibilityCriteria":72,"healthyVolunteers":68,"sex":73,"minAge":74,"maxAge":10,"enrollmentInfo":75,"targetDuration":78,"studyType":79,"phases":10,"briefSummary":80,"conditions":81,"keywords":83,"overallStatus":50,"whyStopped":10,"lastUpdateSubmitDate":87,"lastUpdatePostDateStruct":88,"startDateStruct":91,"completionDateStruct":93,"leadSponsor":95,"locationsCount":96},{"fullName":5,"class":6},"Czech Lymphoma Study Group","OTHER",[8,12,15,18,21,24,27,30],{"label":9,"type":10,"description":11,"interventionNames":10},"All NHL subtypes",null,"no interventions",{"label":13,"type":10,"description":14,"interventionNames":10},"DLBCL","only patients with diffuse large B-cell lymphoma",{"label":16,"type":10,"description":17,"interventionNames":10},"FL","only patients with follicular lymphoma",{"label":19,"type":10,"description":20,"interventionNames":10},"MCL","only patients with mantle cell lymphoma",{"label":22,"type":10,"description":23,"interventionNames":10},"SLL\u002FCLL","only patients with small lymphocytic lymphoma \u002F chronic lymphocytic leukemia",{"label":25,"type":10,"description":26,"interventionNames":10},"MZL","only patients with marginal zone lymphoma",{"label":28,"type":10,"description":29,"interventionNames":10},"other B-cell lymphomas","only patients with B-lymphomas not described above",{"label":31,"type":10,"description":32,"interventionNames":10},"T-cell lymphomas","only patients with all types of T-cell lymphoma",[34],{"name":35,"affiliation":36,"role":37},"Marek Trneny, prof. MD","Charles University General Hospital, Prague, CZ","PRINCIPAL_INVESTIGATOR",[39,43],{"name":35,"role":40,"phone":41,"phoneExt":10,"email":42},"CONTACT","+420224962061","trneny@cesnet.cz",{"name":44,"role":40,"phone":45,"phoneExt":10,"email":46},"David Belada, MD","+420495 832 866","david.belada@seznam.cz",[48],{"facility":49,"status":50,"city":51,"state":10,"zip":52,"country":53,"countryCode":10,"cosmosGeoPoint":54,"geoPoint":59,"contacts":60},"Charles University General Hospital","RECRUITING","Prague","128 08","Czechia",{"type":55,"coordinates":56},"Point",[57,58],14.42076,50.08804,{"lat":58,"lon":57},[61,63],{"name":62,"role":40,"phone":41,"phoneExt":10,"email":42},"Marek Trneny, prof.MD",{"name":44,"role":40,"phone":45,"phoneExt":10,"email":46},{"type":65,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100301053","non-hodgkin-lymphoma---observational-epidemiological-and-clinical-study-nihil-100301053",false,"NCT03199066","Non-Hodgkin Lymphoma - Observational Epidemiological and Clinical Study (NiHiL)","The Incidence, Epidemiology, Clinical Characteristic, Prognostic Factors, Therapy and Outcome of Non-Hodgkin Lymphoma Patients in the Czech Republic. NiHiL- Longitudinal Observational Study of Czech Lymphoma Study Group (CLSG)","Inclusion Criteria:\n\n* lymphoma diagnosis\n* treated in the Czech Republic\n* signed informed consent\n\nExclusion Criteria:\n\n* unsigned informed consent\n* age \\\u003C18 y","ALL","18 Years",{"count":76,"type":77},20000,"ESTIMATED","10 Years","OBSERVATIONAL","The Czech National Lymphoma Registry (NiHiL) was founded to monitor epidemiologic data and improve the diagnostic evaluation and quality of treatment of patients with non-Hodgkin´s lymphoma (NHL).\n\nThe patients are registered into the registry in anonymized form. For each patient are available: registration form, diagnostic form, treatment form, follow- up form, and other malignancy form.\n\nData quality in the NiHiL has been checked by audits. The data is analyzed according to NHL subtypes with endpoints: lymphoma distribution, epidemiological data, prognostic characteristic, treatment characteristics, response rate, relapse rate, mortality, PFS, OS, DFS, Lymphoma specific survival, longterm toxicity.",[82],"Non Hodgkin Lymphoma (NHL)",[84,85,86],"survival","therapy","epidemiology","2017-06-21",{"date":89,"type":90},"2017-06-26","ACTUAL",{"date":92,"type":90},"1999-01-01",{"date":94,"type":77},"2027-12-31",{"name":5,"class":6},1]